A revival of bispecific antibodies

Kufer, Peter; Lutterbüse, Ralf; Baeuerle, Patrick A.

doi:10.1016/j.tibtech.2004.03.006

Cited by 157Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and ImmunotoxinsBiochemical and Structural Characterization

A revival of bispecific antibodies

Kufer, Peter, Lutterbüse, Ralf, Baeuerle, Patrick A.·2004·Trends in Biotechnology

DOI 10.1016/j.tibtech.2004.03.006

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/j.tibtech.2004.03.006

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Early bispecific antibody approaches using chemical cross-linking or hybrid hybridomas/quadromas did not lead to a significant impact in the clinical course of disease despite some biological effects.
“Despite some obvious biological effects, none of these approaches led to a significant impact in the clinical course of disease. 8”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [8]

Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200 · see citing works
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
McLaughlin, P. J., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence‐Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,752 · see citing works
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D. L., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,066 · see citing works
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E. H., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899 · see citing works
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 879 · see citing works
Overweight as an avoidable cause of cancer in Europe
Bergström, A., Pisani, P., Tenet, V., Wolk, A., & Adami, H. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999 · Cited by 772 · see citing works
IgA Fc Receptors
Monteiro, R. C., & van de Winkel, J. G. J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141011 · Cited by 533 · see citing works
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 519 · see citing works
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A. D., Adams, C. W., Presta, L. G., & Carter, P. M. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 513 · see citing works
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492 · see citing works
A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
Löffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445 · see citing works
Self-citation
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Fishelson, Z. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00112-3 · Cited by 409 · see citing works
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351 · see citing works
Self-citation
Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody
Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmüller, G., Bargou, R. C., & Baeuerle, P. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10557 · Cited by 348 · see citing works
Self-citation
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M. (1985) · Nature · doi:10.1038/316354a0 · Cited by 337 · see citing works
MHC antigens and tumor escape from immune surveillance
Garrido, F., & Algarra, I. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305 · see citing works
Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
Glennie, M. J., McBride, H. M., Worth, A. T., & Stevenson, G. T. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.7.2367 · Cited by 263 · see citing works
Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G 1 Fragments
Brennan, M., Davison, P. F., & Paulus, H. (1985) · Science · doi:10.1126/science.3925553 · Cited by 252 · see citing works
Preliminary trial of specific targeting therapy against malignant glioma
Nitta, T., Yagita∥, H., Okumura, K., Sato, K., & Ishii, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90205-j · Cited by 235 · see citing works
Food groups and risk of oral and pharyngeal cancer
Levi, F., Pasche, C., Vecchia, C. L., Lucchini, F., Franceschi, S., & Monnier, P. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980831)77:5 · Cited by 228 · see citing works
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · see citing works
Formation of a bispecific antibody by the use of leucine zippers
Kostelny, S. A., Cole, M. S., & Tso, J. Y. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.5.1547 · Cited by 211 · see citing works
Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.
Staerz, U. D., & Bevan, M. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1453 · Cited by 208 · see citing works
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., von der Lieth, C., Matys, E., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202 · see citing works
T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct
Dreier, T., Baeuerle, P. A., Fichtner, I., Grün, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbüse, R., Riethmüller, G., Gjorstrup, P., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.8.4397 · Cited by 191 · see citing works
Self-citation
Crystal structure of a diabody, a bivalent antibody fragment
Perišić, O., Webb, P. A., Holliger, P., Winter, G. P., & Williams, R. L. (1994) · Structure · doi:10.1016/s0969-2126(94)00123-5 · Cited by 189 · see citing works
Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody
Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Re, E. D., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1463 · Cited by 187 · see citing works
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V. A., Deo, Y. M., Graziano, R. F., Fisher, J. L., Meyer, L. A., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180 · see citing works
The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds
Schuurman, J., Perdok, G. J., Gorter, A. D., & Aalberse, R. C. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00050-5 · Cited by 174 · see citing works
Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy
Valerius, T., Repp, R., de Wit, T., Berthold, S., Platzer, E., Kalden, J., Gramatzki, M., & van de Winkel, J. G. J. (1993) · Blood · doi:10.1182/blood.v82.3.931.bloodjournal823931 · Cited by 165 · see citing works
Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.
Karpovsky, B., Titus, J. A., Stephany, D. A., & Segal, D. M. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.6.1686 · Cited by 162 · see citing works
[17] Bispecific monoclonal antibodies from hybrid hybridomas
Suresh, M. R., Cuello, A. C., & Milstein, C. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)21019-8 · Cited by 160 · see citing works
Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
Renner, C., Jung, W. E., Şahin, U., Denfeld, R. W., Pohl, C., Trümper, L. H. P., Hartmann, F., Diehl, V., van Lier, R. A. W., & Pfreundschuh, M. G. (1994) · Science · doi:10.1126/science.8171337 · Cited by 156 · see citing works
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
Löffler, A., Gruen, M., Wuchter, C., Schriever, F., Kufer, P., Dreier, T., Hanakam, F., Baeuerle, P. A., Bommert, K., Karawajew, L., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402890 · Cited by 150 · see citing works
Self-citation
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M. (1997) · Blood · doi:10.1182/blood.v89.6.2042 · Cited by 149 · see citing works
Clinical experience with CD64-directed immunotherapy. An overview
Curnow, R. T. (1997) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050435 · Cited by 141 · see citing works
Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner, L. M., Clark, J. I., Davey, M., Li, W. S., de Palazzo, I. G., Ring, D. B., & Alpaugh, R. K. (1995) · PubMed · Cited by 139 · see citing works
Construction, expression, and activity of a bivalent bispecific single-chain antibody.
Mallender, W. D., & Voss, E. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42334-9 · Cited by 122 · see citing works
Polymorphonuclear leukocyte function triggered through the high affinity Fc receptor for monomeric IgG.
Shen, L., Guyre, P. M., & Fanger, M. W. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.2.534 · Cited by 122 · see citing works
High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli
Zhu, Z., Zapata, G. A., Shalaby, R., Snedecor, B., Chen, H., & Carter, P. M. (1996) · Nature Biotechnology · doi:10.1038/nbt0296-192 · Cited by 122 · see citing works
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.
Bolhuis, R. L. H., Lamers, C. H., Goey, S. H., Eggermont, A. M. M., Trimbos, J. B. M. Z., Stoter, G., Lanzavecchia, A., Re, E. D., Miotti, S., & Raspagliesi, F. (1992) · PubMed · Cited by 108 · see citing works
A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer
James, N. D., Atherton, P. J., Jones, J. L., Howie, A. J., Tchekmedyian, S., & Curnow, R. T. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1878 · Cited by 100 · see citing works
Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
Hartmann, F., Renner, C., Jung, W. E., Costa, L. M. D., Tembrink, S., Held, G., Sek, A., König, J., Bauer, S., Kloft, M., et al. (2001) · PubMed · Cited by 99 · see citing works
Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli.
Gruber, M., Schodin, B. A., Wilson, E. R., & Kranz, D. M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.11.5368 · Cited by 98 · see citing works
Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library
de Kruif, J., & Logtenberg, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7630 · Cited by 93 · see citing works
Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J. J. G., Schuhmacher, J., Benner, A., Moldenhauer, G., & Little, M. (2000) · PubMed · Cited by 91 · see citing works
Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity
Mack, M., Gruber, R., Schmidt, S., Riethmüller, G., & Kufer, P. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3965 · Cited by 86 · see citing works
Self-citation
Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice.
Titus, J. A., Garrido, M. A., Hecht, T. T., Winkler, D. F., Wunderlich, J. R., & Segal, D. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.11.4018 · Cited by 85 · see citing works
A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo
Hombach, A. A., Jung, W. E., Pohl, C., Renner, C., Şahin, U., Schmits, R., Wolf, J., Kapp, U., Diehl, V., & Pfreundschuh, M. G. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550523 · Cited by 85 · see citing works
Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-hodgkin lymphoma
Wiseman, G. A., Leigh, B. R., Erwin, W. D., Lamonica, D. M., Kornmehl, E., SPIES, S. M., Silverman, D. H. S., Witzig, T. E., Sparks, R. B., & White, C. A. (2002) · Cancer · doi:10.1002/cncr.10305 · Cited by 84 · see citing works
Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2
Kroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R., van der Graaf, W., The, T., de Leij, L., & Mulder, N. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.366 · Cited by 82 · see citing works
The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies
Müller, K. M., Arndt, K. M., Strittmatter, W., & Plückthun, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00021-0 · Cited by 78 · see citing works
Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components
Mezzanzanica, D., Canevari, S., Ménard, S., Pupa, S. M., Tagliabue, E., Lanzavecchia, A., & COLNAGHI, M. I. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410422 · Cited by 74 · see citing works
Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity
McCall, A. M., Shahied, L., Amoroso, A. R., Horak, E. M., Simmons, H. H., Nielson, U., Adams, G. P., Schier, R., Marks, J. D., & Weiner, L. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.10.6112 · Cited by 72 · see citing works
The Crystal Structure of an Anti-CEA scFv Diabody Assembled from T84.66 scFvs in VL-to-VH Orientation: Implications for Diabody Flexibility
Carmichael, J. A., Power, B. E., Garrett, T., Yazaki, P. J., Shively, J. E., Raubischek, A. A., Wu, A. M., & Hudson, P. J. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01428-6 · Cited by 70 · see citing works
Clinical Experience with CD3 X CD19 Bispecific Antibodies in Patients with B Cell Malignancies
GAST, G. C. D., van Houten, A. A., Haagen, I.-A., Klein, S. C., de Weger, R. A., DIJK, A. V., PHILLIPS, J., Clark, M., & Bast, B. J. E. G. (1995) · Journal of Hematotherapy · doi:10.1089/scd.1.1995.4.433 · Cited by 68 · see citing works
Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma
Weiner, G. J., & Hillstrom, J. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.4035 · Cited by 67 · see citing works
Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma
Honeychurch, J., Tutt, A. L., Valerius, T., Heijnen, I., van de Winkel, J. G. J., & Glennie, M. J. (2000) · Blood · doi:10.1182/blood.v96.10.3544 · Cited by 62 · see citing works
Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
Deo, Y. M., Sundarapandiyan, K., Keler, T., Wallace, P. K., & Graziano, R. F. (1998) · PubMed · Cited by 61 · see citing works
Bispecific Molecules Directed to the Fc Receptor for IgA (FcαRI, CD89) and Tumor Antigens Efficiently Promote Cell-Mediated Cytotoxicity of Tumor Targets in Whole Blood
Deo, Y. M., Sundarapandiyan, K., Keler, T., Wallace, P. K., & Graziano, R. F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1677 · Cited by 59 · see citing works
Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma
Marmé, A., Strauß, G., Bastert, G., Grischke, E., & Moldenhauer, G. (2002) · International Journal of Cancer · doi:10.1002/ijc.10562 · Cited by 58 · see citing works
Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies
Kipriyanov, S. M., Moldenhauer, G., Braunagel, M., Reusch, U., Cochlovius, B., Gall, F. L., Kouprianova, O. A., von der Lieth, C., & Little, M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00526-6 · Cited by 57 · see citing works
A Bispecific Monoclonal Antibody Directed Against Both the Membrane-Bound Complement Regulator CD55 and the Renal Tumor-Associated Antigen G250 Enhances C3 Deposition and Tumor Cell Lysis by Complement
Blok, V. T., Daha, M. R., Tijsma, O., Harris, C. L., Morgan, B. P., Fleuren, G. J., & Gorter, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3437 · Cited by 52 · see citing works
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
Kufer, P., Mack, M., Gruber, R., Lutterbüse, R., Zettl, F., & Riethmüller, G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050431 · Cited by 51 · see citing works
Self-citation
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab
Zelenetz, A. D. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70054-2 · Cited by 51 · see citing works
Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle, P. A., Kufer, P., & Lutterbüse, R. (2003) · PubMed · Cited by 50 · see citing works
Self-citation
Clinical Trials of Bispecific Antibody MDX-210 in Women with Advanced Breast or Ovarian Cancer that Overexpresses HER-2/neu
VALONE, F. H., KAUFMAN, P. A., GUYRE, P. M., LEWIS, L. D., MEMOLI, V., ERNSTOFF, M. S., WELLS, W., BARTH, R., DEO, Y., FISHER, J., et al. (1995) · Journal of Hematotherapy · doi:10.1089/scd.1.1995.4.471 · Cited by 48 · see citing works
Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation
Demanet, C., Brissinck, J., Jonge, J. D., & Thielemans, K. (1996) · Blood · doi:10.1182/blood.v87.10.4390.bloodjournal87104390 · Cited by 47 · see citing works
Transfer of Immune Complexes from Erythrocyte CR1 to Mouse Macrophages
Reinagel, M. L., & Taylor, R. P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1977 · Cited by 45 · see citing works
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab
Zelenetz, A. D. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.23803 · Cited by 45 · see citing works
Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies
Heijnen, I., Rijks, L. J. M., Schiel, A. E., Stockmeyer, B., van Ojik, H. H., Dechant, M., Valerius, T., Keler, T., Tutt, A. L., Glennie, M. J., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5629 · Cited by 44 · see citing works
Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
Zhu, H. J., Jain, R. K., & Baxter, L. T. (1998) · PubMed · Cited by 41 · see citing works
Alemtuzumab therapy in B-cell lymphoproliferative disorders
Moreton, P., & Hillmen, P. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00253-7 · Cited by 40 · see citing works
A Pilot Trial of GM-CSF and MDX-H210 in Patients with erbB-2-Positive Advanced Malignancies
Posey, J. A., Raspet, R., Verma, U. N., Deo, Y. M., Keller, T., Marshall, J. L., Hodgson, J., Mazumder, A., & Hawkins, M. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199907000-00011 · Cited by 39 · see citing works
In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 × Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model
Jonge, J. D., Heirman, C., Veerman, M. D., Meirvenne, S. V., Moser, M., Léo, O., & Thielemans, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.3.1454 · Cited by 38 · see citing works
Immune adherence and the processing of soluble complement-fixing antibody/DNA immune complexes in mice
Edberg, J. C., Tosic, L., & Taylor, R. P. (1989) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(89)90212-2 · Cited by 35 · see citing works
Targeting of Human Breast Cancer by a Bispecific Antibody Directed against Two Tumour-Associated Antigens: ErbB-2 and Carcinoembryonic Antigen
Dorvillius, M., Garambois, V., Pourquier, D., Gutowski, M., Rouanet, P., Mani, J. C., Pugnière, M., Hynes, N. E., & Pèlegrin, A. (2002) · Tumor Biology · doi:10.1159/000069793 · Cited by 34 · see citing works
Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies
French, R. R., Penney, C., Browning, A. C., Stirpe, F., George, A., & Glennie, M. J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.190 · Cited by 33 · see citing works
Cytolytic and cytostatic properties of an anti-human Fc γRI (CD64) x epidermal growth factor bispecific fusion protein
Goldstein, J., Graziano, R. F., Sundarapandiyan, K., Somasundaram, C., & Deo, Y. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.2.872 · Cited by 31 · see citing works
A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL
Jost, C. R., Titus, J. A., Kurucz, I., & Segal, D. M. (1996) · Molecular Immunology · doi:10.1016/0161-5890(95)00087-9 · Cited by 29 · see citing works
Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell linesin vitro andin vivo
Ford, C. H. J., Osborne, P. A., Rego, B., & Mathew, A. (2001) · International Journal of Cancer · doi:10.1002/ijc.1262 · Cited by 27 · see citing works
Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fcγ RIII
Weiner, L. M., Alpaugh, R. K., Amoroso, A. R., Adams, G. P., Ring, D. B., & Barth, M. W. (1996) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050264 · Cited by 20 · see citing works
Tumor Therapy with Bispecific Antibody: The Targeting and Triggering Steps Can Be Separated Employing a CD2-Based Strategy
Wild, M. K., Strittmatter, W., Matzku, S., Schraven, B. L., & Meuer, S. C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.2064 · Cited by 17 · see citing works
Function-specific variations in the immunological synapses formed by cytotoxic T cells
Irvine, D. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536626100 · Cited by 12 · see citing works
Alternative Triggering Molecules and Single Chain Bispecific Antibodies
Segal, D. M., Sconocchia, G., TITUS, J. A., Jost, C. R., & KURUCZ, I. (1995) · Journal of Hematotherapy · doi:10.1089/scd.1.1995.4.377 · Cited by 11 · see citing works
Approaches to implement bispecific antibody treatment of ovarian carcinoma
Canevari, S., Mezzanzanica, D., Mazzoni, A., Negri, D. R. M., Figini, M., Ramakrishna, V., Bolis, G., & COLNAGHI, M. I. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050429 · Cited by 10 · see citing works

Flagged first, then by citations

3 of the 89 references couldn’t be matched to a known paper.

Sorted by citations

The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 933 · see citing works
Bispecific antibodies
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 585 · see citing works
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Boström, J., Yu, S., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K. L., Man, W., Peale, F. V., Jr., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 372 · see citing works
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct
Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344 · see citing works
Self-citation
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Hua, Y., Grinnell, C. M., Bryant, S. H., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L. C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344 · see citing works
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S. A. B. W., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 340 · see citing works
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336 · see citing works
Monoclonal TCR-redirected tumor cell killing
Liddy, N., Bossi, G., Adams, K. J., Lissina, A., Mahon, T., Hassan, N. J., Gavarret, J., Bianchi, F., Pumphrey, N. J., Ladell, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2764 · Cited by 327 · see citing works
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260 · see citing works
Self-citation
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256 · see citing works
Self-citation
Non-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225 · see citing works
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Ellerman, D. A. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.026 · Cited by 197 · see citing works
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†
Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194 · see citing works
Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class
Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187 · see citing works
Self-citation
A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity
Lu, D., Zhang, H., Koo, H., Tonra, J. R., Balderes, P. J., Prewett, M. C., Corcoran, E., Mangalampalli, V. R. M., Bassi, R., Anselma, D. J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500815200 · Cited by 180 · see citing works
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144 · see citing works
Recombinant bispecific antibodies for cancer therapy
Kontermann, R. E. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00008.x · Cited by 142 · see citing works
Bispecific Antibodies for Cancer Immunotherapy: Current Perspectives
Müller, D., & Kontermann, R. E. (2010) · BioDrugs · doi:10.2165/11530960-000000000-00000 · Cited by 137 · see citing works
Engineering antibodies for clinical applications
Jain, M., Kamal, N., & Batra, S. K. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.05.001 · Cited by 129 · see citing works
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 116 · see citing works
Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design
Deyev, S. M., & Lebedenko, E. N. (2008) · BioEssays · doi:10.1002/bies.20805 · Cited by 109 · see citing works
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
Mølhøj, M., Crommer, S., Brischwein, K., Rau, D., Sriskandarajah, M., Hoffmann, P., Kufer, P., Hofmeister, R., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.032 · Cited by 104 · see citing works
Self-citation
Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
Ruf, P., Gires, O., Jäger, M., Fellinger, K., Atz, J., & Lindhofer, H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603881 · Cited by 102 · see citing works
Breast cancer immunotherapy: Current and novel approaches
Barzaman, K., Moradi‐Kalbolandi, S., Hosseinzadeh, A., Kazemi, M. H., Khorramdelazad, H., Safari, E., & Farahmand, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107886 · Cited by 100 · see citing works
Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling
Jackman, J. K., Chen, Y., Huang, A. J. Y., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113910 · Cited by 91 · see citing works
Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
Amann, M., Brischwein, K., Lutterbuese, P., Parr, L., Petersen, L., Lorenczewski, G., Krinner, E., Bruckmeier, S., Lippold, S., Kischel, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2182 · Cited by 90 · see citing works
Self-citation
Therapeutic targets and recent advances in protein immunotoxins
Madhumathi, J., & Verma, R. S. (2012) · Current Opinion in Microbiology · doi:10.1016/j.mib.2012.05.006 · Cited by 89 · see citing works
Bispecific antibodies engage T cells for antitumor immunotherapy
Choi, B. D., Cai, M., Bigner, D. D., Mehta, A. I., Kuan, C.-T., & Sampson, J. H. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.572874 · Cited by 88 · see citing works
Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013474 · Cited by 85 · see citing works
Self-citation
Production of stable bispecific IgG1 by controlled Fab-arm exchange
Gramer, M. J., van den Bremer, E. T. J., van Kampen, M. D., Kundu, A., Kopfmann, P., Etter, E., Stinehelfer, D., Long, J., Lannom, T., Noordergraaf, E. H., et al. (2013) · mAbs · doi:10.4161/mabs.26233 · Cited by 83 · see citing works
Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.004 · Cited by 83 · see citing works
Advances in bispecific biotherapeutics for the treatment of cancer
May, C., Sapra, P., & Gerber, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.011 · Cited by 77 · see citing works
Bispecific Antibodies: Molecules That Enable Novel Therapeutic Strategies
Fischer, N., & Léger, O. J. P. (2007) · Pathobiology · doi:10.1159/000101046 · Cited by 77 · see citing works
A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism
Liu, Z., Leng, E. C., Gunasekaran, K., Pentony, M., Shen, M., Howard, M., Stoops, J. D., Manchulenko, K., Razinkov, V. I., Liu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620260 · Cited by 75 · see citing works
Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies
Liu, Z., Gunasekaran, K., Wang, W., Razinkov, V. I., Sekirov, L., Leng, E. C., Sweet, H., Foltz, I. N., Howard, M., Rousseau, A.-M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513366 · Cited by 75 · see citing works
Humanization of the Bispecific Epidermal Growth Factor Receptor × CD3 Diabody and Its Efficacy as a Potential Clinical Reagent
Asano, R., Sone, Y., Makabe, K., Tsumoto, K., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., & Kumagai, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0059 · Cited by 72 · see citing works
Modern Technologies for Creating Synthetic Antibodies for Clinical Application
Deyev, S. M., & Lebedenko, E. N. (2009) · Acta Naturae · doi:10.32607/20758251-2009-1-1-32-50 · Cited by 74 · see citing works
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
Emanuel, S. L., Engle, L. J., Chao, G., Zhu, R.-R., Cao, C., Lin, Z., Yamniuk, A. P., Hosbach, J., Brown, J. M., Fitzpatrick, E., et al. (2011) · mAbs · doi:10.4161/mabs.3.1.14168 · Cited by 72 · see citing works
Overcoming Instability of Antibody‐Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies
Howard, C. B., Fletcher, N. L., Houston, Z. H., Fuchs, A. V., Boase, N. R. B., Simpson, J. D., Raftery, L. J., Ruder, T., Jones, M. L., de Bakker, C. J., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600263 · Cited by 70 · see citing works
Man-made antibodies and immunoconjugates with desired properties: function optimization using structural engineering
Deyev, S. M., Lebedenko, E. N., Petrovskaya, L. E., Dolgikh, D. A., Gabibov, A. G., & Kirpichnikov, M. P. (2014) · Russian Chemical Reviews · doi:10.1070/rcr4459 · Cited by 68 · see citing works
Engineering and characterization of a bispecific HER2 × EGFR‐binding affibody molecule
Friedman, M., Lindström, S., Ekerljung, L., Svahn, H. A., Carlsson, J., Brismar, H., Gedda, L., Frejd, F. Y., & Ståhl, S. (2009) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090096 · Cited by 65 · see citing works
Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases
An, Z. (2010) · Protein & Cell · doi:10.1007/s13238-010-0052-8 · Cited by 62 · see citing works
A pivotal decade for bispecific antibodies?
Surowka, M., & Klein, C. (2024) · mAbs · doi:10.1080/19420862.2024.2321635 · Cited by 64 · see citing works
DARPins as Bispecific Receptor Antagonists Analyzed for Immunoglobulin E Receptor Blockage
Eggel, A., Baumann, M. J., Amstutz, P., Stadler, B. M., & Vogel, M. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.08.014 · Cited by 58 · see citing works
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and α v β 3 integrin
Papo, N., Silverman, A. P., Lahti, J. L., & Cochran, J. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016635108 · Cited by 58 · see citing works
Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells
Asano, R., Watanabe, Y., Kawaguchi, H., Fukazawa, H., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704719200 · Cited by 56 · see citing works
Bispecific Monoclonal Antibody-Based Multianalyte ELISA for Furaltadone Metabolite, Malachite Green, and Leucomalachite Green in Aquatic Products
Wang, F., Wang, H., Shen, Y., Li, Y., Dong, J.-X., Xu, Z., Yang, J., Sun, Y., & Xiao, Z. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b03233 · Cited by 54 · see citing works
The renaissance of chemically generated bispecific antibodies
Szijj, P. A., & Chudasama, V. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-020-00241-6 · Cited by 54 · see citing works
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
Schlereth, B., Kleindienst, P., Fichtner, I., Lorenczewski, G., Brischwein, K., Lippold, S., da Silva, A., Locher, M., Kischel, R., Lutterbüse, R., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0082-x · Cited by 54 · see citing works
Self-citation
Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies
Muda, M., Gross, A. W., Dawson, J., He, C., Kurosawa, E., Schweickhardt, R. L., Dugas, M., Soloviev, M., Bernhardt, A., Fischer, D., et al. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq123 · Cited by 52 · see citing works
Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer
Fournier, P., & Schirrmacher, V. (2012) · BioDrugs · doi:10.1007/s40259-012-0008-z · Cited by 52 · see citing works
Fab-PEG-Fab as a Potential Antibody Mimetic
Khalili, H., Godwin, A., Choi, J.-W., Lever, R., Khaw, P. T., & Brocchini, S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400246z · Cited by 49 · see citing works
Chemically Synthesized Molecules with the Targeting and Effector Functions of Antibodies
McEnaney, P. J., Fitzgerald, K., Zhang, A. X., Douglass, E. F., Shan, W., Balog, A., Kolesnikova, M. D., & Spiegel, D. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja509513c · Cited by 50 · see citing works
Next generation immunotherapeutics—honing the magic bullet
Enever, C., Batuwangala, T. D., Plummer, C., & Sepp, A. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.07.002 · Cited by 49 · see citing works
Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion
Buhmann, R., Simoes, B., Stanglmaier, M., Yang, T., Faltin, M., Bund, D., Lindhofer, H., & Kolb, H.-J. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.323 · Cited by 48 · see citing works
Optimization of bulk cell electrofusion in vitro for production of human–mouse heterohybridoma cells
Trontelj, K. J., Reberšek, M., Kandušer, M., Šerbec, V. Č., Šprohar, M., & Damijan Miklavčič, A. (2008) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2008.06.003 · Cited by 42 · see citing works
Recombinant polyclonal antibodies for cancer therapy
Sharon, J., Liebman, M. A., & Williams, B. R. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20536 · Cited by 41 · see citing works
Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody
Asano, R., Kumagai, T., Nagai, K., Taki, S., Shimomura, I., Arai, K., Ogata, H., Okada, M., Hayasaka, F., Sanada, H., et al. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt009 · Cited by 40 · see citing works
The intriguing options of multispecific antibody formats for treatment of cancer.
Weidle, U. H., Tiefenthaler, G., Weiss, E. H., Georges, G. J., & Brinkmann, U. (2013) · PubMed · Cited by 40 · see citing works
A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
Lee, S. C., Ma, J. S. Y., Kim, M. S., Laborda, E., Choi, S., Hampton, E. N., Yun, H., Núñez, V., Muldong, M. T., Wu, C. N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8193 · Cited by 40 · see citing works
Bispecific Antibodies for Cancer Therapy
Hollander, N. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.211 · Cited by 38 · see citing works
Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond
Luo, H., Hong, H., Yang, S. P., & Cai, W. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500115x · Cited by 38 · see citing works
Bispecific antibody process development: Assembly and purification of knob and hole bispecific antibodies
Giese, G. S., Williams, A. J., Rodriguez, M., & Persson, J. (2017) · Biotechnology Progress · doi:10.1002/btpr.2590 · Cited by 36 · see citing works
Evolving antibody therapies for the treatment of type 1 diabetes
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624568 · Cited by 44 · see citing works
Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
Tabrizi, M. A., Funelas, C. B., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9220-2 · Cited by 35 · see citing works
Immunotherapy with the trifunctional anti‐ CD 20 x anti‐ CD 3 antibody FBTA 05 (Lymphomun) in paediatric high‐risk patients with recurrent CD 20‐positive B cell malignancies
Schuster, F. R., Stanglmaier, M., Woessmann, W., Winkler, B., Siepermann, M., Meisel, R., Schlegel, P. G., Hess, J., Lindhofer, H., Borkhardt, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13242 · Cited by 33 · see citing works
An Integrated Approach to Aggregate Control for Therapeutic Bispecific Antibodies Using an Improved Three Column Mab Platform‐Like Purification Process
Andrade, C., Arnold, L., Motabar, D., Aspelund, M. T., Tang, A., Hunter, A. K., & Chung, W. K. (2018) · Biotechnology Progress · doi:10.1002/btpr.2720 · Cited by 33 · see citing works
Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system
Asano, R., Nakayama, M., Kawaguchi, H., Kubota, T., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., et al. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08417.x · Cited by 33 · see citing works
Modern Antibody Technology: The Impact on Drug Development
Moroney, S. E., & Plückthun, A. (2005) · Wiley eBooks · doi:10.1002/9783527620982.ch48 · Cited by 32 · see citing works
Diabody-based Recombinant Formats of Humanized IgG-like Bispecific Antibody With Effective Retargeting of Lymphocytes to Tumor Cells
Asano, R., Kawaguchi, H., Watanabe, Y., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., & Kumagai, I. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181849071 · Cited by 31 · see citing works
Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity
Tustian, A. D., Laurin, L., Ihre, H. R., Tran, T., Stairs, R., & Bak, H. (2018) · Biotechnology Progress · doi:10.1002/btpr.2622 · Cited by 31 · see citing works
Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
Stamova, S., Koristka, S., Keil, J., Arndt, C., Feldmann, A., Michalk, I., Bartsch, H., Bippes, C. C., Schmitz, M., Cartellieri, M., et al. (2012) · Antibodies · doi:10.3390/antib1020172 · Cited by 30 · see citing works
Application of the Fc fusion format to generate tag‐free bi‐specific diabodies
Asano, R., Ikoma, K., Kawaguchi, H., Ishiyama, Y., Nakanishi, T., Umetsu, M., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., et al. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07499.x · Cited by 28 · see citing works
Cytotoxic Enhancement of a Bispecific Diabody by Format Conversion to Tandem Single-chain Variable Fragment (taFv)
Asano, R., Ikoma, K., Shimomura, I., Taki, S., Nakanishi, T., Umetsu, M., & Kumagai, I. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172957 · Cited by 28 · see citing works
Highly Enhanced Cytotoxicity of a Dimeric Bispecific Diabody, the hEx3 Tetrabody
Asano, R., Ikoma, K., Sone, Y., Kawaguchi, H., Taki, S., Hayashi, H., Nakanishi, T., Umetsu, M., Katayose, Y., Unno, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.120444 · Cited by 28 · see citing works
A Novel Bispecific Antibody, S-Fab, Induces Potent Cancer Cell Killing
Li, L., He, P., Zhou, C., Jing, L., Dong, B., Chen, S., Zhang, N., Liu, Y., Miao, J. H., Wang, Z., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000099 · Cited by 27 · see citing works
Use of SpyTag/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen
Yumura, K., Akiba, H., Nagatoishi, S., Kusano‐Arai, O., Iwanari, H., Hamakubo, T., & Tsumoto, K. (2017) · The Journal of Biochemistry · doi:10.1093/jb/mvx023 · Cited by 26 · see citing works
The current status of immunotherapy in peritoneal carcinomatosis
Ströhlein, M. A., Heiss, M. M., & Jauch, K. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1224666 · Cited by 25 · see citing works
Alkaline cation-exchange chromatography for the reduction of aggregate and a mis-formed disulfide variant in a bispecific antibody purification process
Hall, T., Wilson, J. J., Brownlee, T. J., Swartling, J. R., Langan, S. E., & Lambooy, P. K. (2014) · Journal of Chromatography B · doi:10.1016/j.jchromb.2014.11.002 · Cited by 24 · see citing works
Monoclonal Antibodies in Cancer Therapy
Rader, C. M., & Bishop, M. R. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_20 · Cited by 24 · see citing works
Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
Witthauer, J., Schlereth, B., Brischwein, K., Winter, H., Funke, I., Jauch, K., Baeuerle, P. A., & Mayer, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0185-0 · Cited by 23 · see citing works
Self-citation
Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells
Napoleone, A., Laurén, I., Linkgreim, T., Dahllund, L., Persson, H., Andersson, O., Olsson, A., Hultqvist, G., Frank, P., Hall, M. D., et al. (2021) · New Biotechnology · doi:10.1016/j.nbt.2021.07.002 · Cited by 22 · see citing works
Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells
Asano, R., Kuroki, Y., Honma, S., Akabane, M., Watanabe, S., Mayuzumi, S., Hiyamuta, S., Kumagai, I., & Sode, K. (2018) · mAbs · doi:10.1080/19420862.2018.1476815 · Cited by 22 · see citing works
Preparation of an Immunoaffinity Column Based on Bispecific Monoclonal Antibody for Aflatoxin B1 and Ochratoxin A Detection Combined with ic-ELISA
Lu, D., Wang, X., Su, R., Cheng, Y., Wang, H., Luo, L. G., & Xiao, Z. (2022) · Foods · doi:10.3390/foods11030335 · Cited by 21 · see citing works
The Trifunctional Antibody Catumaxomab in Treatment of Malignant Ascites and Peritoneal Carcinomatosis
Ströhlein, M. A., & Heiss, M. M. (2010) · Future Oncology · doi:10.2217/fon.10.111 · Cited by 21 · see citing works
Surrogate approaches in development of monoclonal antibodies
Bornstein, G. G., Klakamp, S. L., Andrews, L., Boyle, W. J., & Tabrizi, M. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.014 · Cited by 20 · see citing works
Tumor-Targeting Antibody–Anticalin Fusion Proteins for in Vivo Pretargeting Applications
Steiner, M., Gutbrodt, K. L., Krall, N., & Neri, D. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300567a · Cited by 19 · see citing works
The making of multispecific immunoglobulins – a clinical perspective
Brinkmann, U., & Kontermann, R. E. (2026) · mAbs · doi:10.1080/19420862.2026.2613548 · Cited by 19 · see citing works
Recent developments in microwave-assisted protein chemistries – can this be integrated into the drug discovery and validation process?
Sandoval, W. N., Pham, V. C., & Lill, J. R. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.08.007 · Cited by 18 · see citing works
Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Dicato, M. A., & Diederich, M. F. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150505124037 · Cited by 17 · see citing works
A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity
Deng, W., Liu, J., Pan, H., Li, L., Zhou, C., Wang, X., Shu, R., Dong, B., Cao, D., Li, Q., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000200 · Cited by 17 · see citing works
Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody
Wulf-Goldenberg, A., Eckert, K., & Fichtner, I. (2010) · Cytotherapy · doi:10.3109/14653249.2010.515577 · Cited by 17 · see citing works
Dual Antibody-Conjugated Amyloid Nanorods to Promote Selective Cell–Cell Interactions
Wang, W., Gil-García, M., & Ventura, S. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c21996 · Cited by 15 · see citing works
Thermoresponsive β-glucan-based polymers for bimodal immunoradiotherapy – Are they able to promote the immune system?
Loukotová, L., Kučka, J., Rabyk, M., Höcherl, A., Venclíková, K., Janoušková, O., Páral, P., Kolářová, V., Heizer, T., Šefc, L., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.010 · Cited by 14 · see citing works
The evolving role of catumaxomab in gastric cancer
Lordick, F., Ott, K., Weitz, J., & Jäger, D. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.9.1407 · Cited by 14 · see citing works
Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528
Asano, R., Sone, Y., Ikoma, K., Hayashi, H., Nakanishi, T., Umetsu, M., Katayose, Y., Unno, M., Kudo, T., & Kumagai, I. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn037 · Cited by 12 · see citing works
Bispecific Aptamer Sensor toward T-Cell Leukemia Detection in the Tumor Microenvironment
Boykoff, N., Freage, L., Lenn, J., & Mallikaratchy, P. R. (2021) · ACS Omega · doi:10.1021/acsomega.1c04125 · Cited by 11 · see citing works
Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Chiarella, P. (2011) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489211795328549 · Cited by 11 · see citing works
A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions
Lü, L., Liu, N., Fan, K., Zhang, G., Li, C., Yan, Y., Liu, T., & Fu, W. H. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.03.001 · Cited by 11 · see citing works
General principles of tumor immunotherapy : basic and clinical applications of tumor immunology
Wolchok, J. D., & Kaufman, H. L. (2007) · Medical Entomology and Zoology · Cited by 11 · see citing works

Authors: Kufer, P., Lutterbüse, R., & Baeuerle, P. A.
Affiliations: Institut für Immunologie (DE)
Corresponding author: Kufer, Peter
ORCID: Baeuerle, Patrick A.
Venue: Trends in Biotechnology
Publisher: Elsevier BV
Published: 2004-05
Volume: 22
Issue: 5
Pages: 238-244
ISSN: 0167-7799 (ISSN-L)
DOI: 10.1016/j.tibtech.2004.03.006
OpenAlex: W2003522381
Cited by: 157
References: 89
Citations by year: 2026: 6 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 8 · 2020: 2 · 2019: 2 · 2018: 6 · 2017: 9 · 2016: 3 · 2015: 6 · 2014: 9 · 2013: 13 · 2012: 9
FWCI: 1.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Trends in biotechnology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
Keywords: bispecific antibodies, cell fusion, cytotoxic effector cells, antibody engineering, cancer immunotherapy, monoclonal antibodies, clinical development
MeSH terms: Antibodies, Monoclonal, Antibody Specificity, Antibody-Dependent Cell Cytotoxicity, Binding Sites, Antibody, Immunoglobulin Fragments, Immunotherapy, Lymphocyte Activation, Recombinant Proteins, Antigens, CD, Antibodies, Bispecific

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A revival of bispecific antibodies

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks